ABILITYPHARMA
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
PIPELINE
ABTL0812, first-in-class, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and lung cancer in Spain and France. 
SCIENCE
AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

ABTL0812 is currently in Phase 2b in in USA, Spain, France and Israel, in a double-blind placebo-controlled clinical trial in 130 patientens with metastatic pancreatic cancer.

Media Center

02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
29.12.2020

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
29.12.2020

In the media

The Chinese SciClone enters at the biotech Ability Pharma + info

Events

June 2-6. 2023 ASCO Annual Meeting. Chicago. + info

Events

May 16-18. BIOMED Israel. The 21st National Life Sciece & Technology Week. Tel Aviv. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG